Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19

El-Sherbiny et al., NCT04477083, NCT04477083, Aug 2020

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.0000000001 from 426 studies, used in 59 countries.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 40 patient HCQ inhaled late treatment RCT with results not reported over 6 years after estimated completion.
37 HCQ RCTs have results missing long after expected1-37
The trials report a total of 20,499 patients, with 12 trials having actual enrollment of 3,639, and the remainder estimated.
El-Sherbiny et al., 15 Aug 2020, Randomized Controlled Trial, trial NCT04477083 (history). Contact: ielsherbiny@zewailcity.edu.eg.
Late treatment
is less effective